Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that its president and chief executive officer, Daniel O’Connor was selected as a winner in the 2015 Ernst & Young (EY) Entrepreneur Of The Year® in New Jersey. Mr. O’Connor was selected by a panel of independent judges and honored at a special event on June 25 at the Hyatt Regency in New Brunswick, N.J.
“New Jersey is home to many of the best biopharmaceutical companies in the world, so there was an incredible caliber of nominees for this award. The hard work, entrepreneurial spirit and innovation showcased by Dan and his team at Advaxis truly stood out, as they not only grew Advaxis, but helped strengthen New Jersey’s reputation for being a world-leader in the life sciences,” said Debbie Hart, president and CEO of BioNJ. “Today, Dan joins a group of gravity-defying entrepreneurs recognized for contributing to the vibrancy of their community.”
“We are so pleased to see Dan recognized for his leadership and commitment to Advaxis,” said Dr. David Sidransky, chairman of the Advaxis board. “It’s an exciting moment for the entire Advaxis team, which has achieved much and works hard to bring innovative immunotherapies to cancer patients.”
As a New Jersey regional award winner, Mr. O’Connor is now eligible for consideration for the EY Entrepreneur of the Year National awards program. Winners will be announced at the annual gala in Palm Springs, Calif., on November 14, 2015. The EY program identifies entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their business and communities. Now in its 29th year, the program has expanded to recognize business leaders in more than 145 cities in more than 60 countries throughout the world.
Founded and produced by EY, the Entrepreneur Of The Year® awards are sponsored nationally by the Ewing Marion Kauffman Foundation and SAP America. In New Jersey, sponsors also include Cresa, DLA Piper, Empire Valuation Consultants, Merrill Corporation, Morgan Lewis, Murray Devine, NJ BIZ, PNC, Scherzer International and SolomonEdwardsGroup.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The LmTechnology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs), that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis’s lead LmTechnology immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted Advaxis orphan drug designation for each of these three indications. For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook,YouTube and Google+.
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis’s ability to develop the next generation of cancer immunotherapies;statements regarding our initiation and completion of enrollment of patients for our studies related to ADXS-HPV, ADXS-PSA and ADXS-HER2, statements regarding preliminary data related to our studies and whether such data is predictive of future clinical trials, and the safety and efficacy of Advaxis’s proprietary immunotherapy, ADXS-HPV. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’s SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2014, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
About EY Entrepreneur Of The Year®
EY Entrepreneur Of The Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.
About EY’s Strategic Growth Markets practice
EY’s Strategic Growth Markets (SGM) practice guides leading high-growth companies. Our multidisciplinary teams of elite professionals provide perspective and advice to help our clients accelerate market leadership. SGM delivers assurance, tax, transactions and advisory services to thousands of companies spanning all industries. EY is the undisputed leader in taking companies public, advising key government agencies on the issues impacting high-growth companies and convening the experts who shape the business climate. For more information, please visit us at ey.com/us/strategicgrowthmarkets, or follow news on Twitter @EY_Growth.
EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.